[Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)].

Abstract

Ten patients with gastro-pancreatic apudomas were prospectively treated with SMS 201-995 at the dose of 25-50 mg/12 h. subcutaneously before breakfast and dinner during two months. The biological and clinical effects were evaluated, as well its possible antitumoral action. When clinical or biological benefit was ascertained, the treatment was continued uninterruptedly. SMS 201-995 was well tolerated. It allows ambulatory treatment. It reduced hormonal levels in 62% of cases and controlled symptoms in 50%. No antitumoral effects were observed in the majority of patients.

• Authors: M J Varas Lorenzo
• Journal: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (Rev Esp Enferm Dig) Vol. 79 Issue 2 Pg. 95-8 (Feb 1991) ISSN: 1130-0108 [Print] Spain
• Vernacular Title: Tratamiento farmacológico de los apudomas gastroenteropancreáticos con el análogo de la somatostatina SMS 201-995 (octreotide).
• PMID: 2059523 (Publication Type: English Abstract, Journal Article)

Chemical References

• Octreotide

Topics

• Aged
• Apudoma (drug therapy)
• Female
• Gastrointestinal Neoplasms (drug therapy)
• Humans
• Male
• Middle Aged
• Octreotide (therapeutic use)
• Pancreatic Neoplasms (drug therapy)
• Prospective Studies